Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Student of the Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Acta Neurol Belg. 2023 Aug;123(4):1209-1223. doi: 10.1007/s13760-022-02141-6. Epub 2022 Nov 16.
This meta-analysis aimed to determine the prevalence, symptoms, and outcomes of COVID-19 in the elderly with Parkinson's disease (PD) by searching in the international databases of PubMed, Scopus, Web of Sciences, and EMBASE using the keywords of "COVID-19" and "Parkinson's." All articles related to Parkinson's disease and COVID-19 from January 2019 to October 20, 2021 were reviewed. The STATA software was used for analysis. A total of 20 articles were selected for data extraction in this meta-analysis, of which ten were cross-sectional studies (to determine the prevalence), five case-control studies, and five cohort studies (to examine the association). The results of the meta-analysis showed the prevalence of COVID-19 in patients with PD was 1.06% (95% CI 1.03-1.1%; P = 0.02), and the prevalence of their hospitalization due to COVID-19 was 0.98% (95% CI: 0.95-1.02%; P = 0.00). Also, the prevalence of depression and anxiety during the pandemic in this group was 46% (95% CI 29-64%; P = 0.00) and 43% (95% CI: 24-63%; P = 0.00), respectively. The prevalence of tremor and sleep problems were higher than those of other symptoms in the studied population. According to the results, there was no significant difference in the risk of COVID-19 infection between Parkinson's patients and healthy people. In other words, the risk of COVID-19 infection was equal in both groups (RR = 1.00 (CI 95% 0.77-1.30%; P = 0.15)). The results showed mortality and hospitalization rates of the elderly with Parkinson's disease were not significantly different from those of the general population during the COVID-19 pandemic. Also, the symptoms of Parkinson's disease and mental disorders increased during the COVID-19 pandemic. So, designing and developing more specific studies, like cohort studies, with large sample size is required for assessing these associations.
这项荟萃分析旨在通过在 PubMed、Scopus、Web of Sciences 和 EMBASE 等国际数据库中搜索“COVID-19”和“帕金森病”等关键词，确定患有帕金森病的老年人 COVID-19 的患病率、症状和结局。综述了 2019 年 1 月至 2021 年 10 月 20 日与帕金森病和 COVID-19 相关的所有文章。使用 STATA 软件进行分析。共有 20 篇文章被纳入本荟萃分析的数据提取，其中 10 篇为横断面研究（确定患病率），5 篇病例对照研究，5 篇队列研究（检查相关性）。荟萃分析的结果表明，PD 患者 COVID-19 的患病率为 1.06%（95%CI 1.03-1.1%；P=0.02），因 COVID-19 住院的患病率为 0.98%（95%CI：0.95-1.02%；P=0.00）。此外，该人群在大流行期间抑郁和焦虑的患病率分别为 46%（95%CI 29-64%；P=0.00）和 43%（95%CI：24-63%；P=0.00）。震颤和睡眠问题的患病率高于研究人群中其他症状的患病率。根据结果，帕金森病患者与健康人群 COVID-19 感染的风险无显著差异。换句话说，两组 COVID-19 感染的风险相等（RR=1.00（95%CI 0.77-1.30%；P=0.15））。结果表明，在 COVID-19 大流行期间，老年帕金森病患者的死亡率和住院率与普通人群没有显著差异。此外，帕金森病症状和精神障碍在 COVID-19 大流行期间有所增加。因此，需要设计和开展更多特定的研究，如队列研究，以评估这些相关性，这些研究应具有更大的样本量。
